Caliway Biopharmaceuticals (6919) Q1 2025 earnings summary

Executive summary

• Focused on new drug development for aesthetic medicine and chronic inflammation, with shares listed on TWSE since October 2024.

• Consolidated financials reviewed by KPMG, with a qualified conclusion due to unreviewed non-significant subsidiaries.

• Board authorized financials on May 5, 2025.

Financial highlights

• Operating revenue for Q1 2025 was $3,966 thousand, up from $0 in Q1 2024.

• Net loss for Q1 2025 was $175,565 thousand, an improvement from $218,472 thousand in Q1 2024.

• Basic loss per share was NT$(0.11) in Q1 2025, compared to NT$(0.16) in Q1 2024.

• Cash and cash equivalents increased to $9,297,482 thousand as of March 31, 2025, from $3,259,789 thousand a year earlier.

• Total assets reached $9,655,679 thousand at March 31, 2025.

Outlook and guidance

• Adoption of new IFRS standards is not expected to have a significant impact.

• The group is evaluating the impact of IFRS 18, effective January 1, 2027.